RxDoctor Payments Data

Rhett Eckmann, MD

Family Medicine · West Point, NENPI 1205922465

Payments from drug & device makers

$230in general payments, 2019–2025

Across 14 payments — averaging $16.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$99
  • AstraZeneca$29
  • Merck$26
  • Novo Nordisk$17
  • Lundbeck LLC$16
  • Amgen$15
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$230100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)5$99
AstraZeneca2$29
Merck2$26
Novo Nordisk1$17
Lundbeck LLC1$16
Amgen1$15
Astellas Pharma US Inc1$14
Novartis1$14

How this compares

$230 in reported general payments places this provider in the 35th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$15,564
Medicare patients
78
Services billed
216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban254$165,769
MounjaroTirzepatide95$94,731
TrulicityDulaglutide88$79,537
JardianceEmpagliflozin66$47,626
XareltoRivaroxaban32$22,302
MyrbetriqMirabegron42$21,223
Tresiba Flextouch U-200Insulin Degludec27$17,848
LokelmaSodium Zirconium Cyclosilicate22$16,762
EntrestoSacubitril/Valsartan23$11,547
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr24$9,869
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$9,680
AbrysvoRsv Vacc, Pref A And Pref B/Pf29$9,293
Breo ElliptaFluticasone/Vilanterol24$9,022
ShingrixVaricella-Zoster Ge/As01b/Pf36$8,047
Combivent RespimatIpratropium/Albuterol Sulfate14$6,789

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma, Brilinta$29$21,93233 claims
Astellas Pharma US IncMyrbetriq$14$21,22342 claims
NovartisEntresto$14$11,54723 claims
MerckJanuvia$26$6,15721 claims
AbbVieLumigan$99$2,99712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 981 family medicine providers in Nebraska.

Other family medicine in West Point

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →